POST Online Media Lite Edition


FDA chief apologizes: Plasma treatment is not so good

Christian Fernsby |
Food and Drug Administration Commissioner Stephen Hahn apologized for overstating benefits of using convalescent plasma to treat coronavirus patients.

Article continues below

Topics: FDA   

Earlier this week, while issuing emergency use authorization or EUA for investigational convalescent plasma to treat coronavirus in hospitalized patients, the FDA had said that the EUA decision was based on scientific data from the preliminary findings of Mayo Clinic observations.

It was also stated that out of 100 people who are sick with coronavirus, 35 would have been saved because of the administration of plasma.

President Donald Trump, in his press briefing to announce the EUA news, on the eve of his Republican National Convention, also called the decision a historic breakthrough.

However, Hahn later tweeted an apology, saying "I have been criticized for remarks I made Sunday night about the benefits of convalescent plasma.

"The criticism is entirely justified.

"What I should have said better is that the data show a relative risk reduction not an absolute risk reduction."

What to read next

FDA to Texas and Arizona: Destroy or export detained shipments of execution drugs
U.S. allows China-made KN95 mask
FDA alerts public to recall of pacemakers vulnerable to cyberattack